134 results about "Inflammasome" patented technology

The present invention relates to the discovery that the disruption of inflammasome function leads to an altered microbiota that affects the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and determining the relative proportions of the constituents of a subject's microbiota, methods of modifying an altered microbiota population in a subject, and compositions and methods for treating inflammatory diseases and disorders in a subject in need thereof.

The invention relates to the molecular biology field and particularly relates to a gene knockout carrier, a construction method and application thereof and a gene knockout method of an NLRP1 gene of an MH7A cell. A CRISPR-Cas9 gene knockout system is utilized for carrying out CRISPR targeting sequence design by taking NLRP1 as a target gene so as to prepare a knockout carrier aiming at the NLRP1 gene, and the knockout carrier is utilized for transfecting the MH7A cell, so that the NLRP1 gene in the MH7A cell can be efficiently knocked out; and therefore, a research platform for rheumatoid arthritis is effectively built, so that the research of the pathogenesis of the rheumatoid arthritis is greatly promoted, and the researches of the interaction of NLRP1 inflammasomes and various inflammatory factors and the disease related molecular mechanisms of the rheumatoid arthritis and meningitis can be promoted.

The invention relates to application of oridonin in preparing drugs for preventing or treating NLRP3 inflammasome-related diseases. The oridonin has a strong pharmacological effect, is safe and innoxious, and indicates a good medicinal prospect. The oridonin can inhibit the activation of an NLRP3 inflammasome in vitro, and can treat pathological conditions of NLRP3 inflammasome-related disease model in vivo. The oridonin can be directly combined with NLRP3 through covalent bonds, thereby inhibiting the interaction of the NLRP3 and NEK7, inhibiting the assembly of the inflammasome, and achieving the purpose of inhibiting the activation of the inflammasome.

The present invention provides compositions and methods for treating or preventing an NLRP3 immunosome-related disorder. In one embodiment, the method includes administering a therapeutically effective amount of a composition comprising at least one NLRP3 inflammasome inhibitor to a subject in need thereof.

The invention includes novel methods of treating or preventing fibrosis in a subject afflicted with scleroderma, comprising administering to the subject a therapeutically effective amount of an agent that inhibits formation of at least one inflammasome signaling product in the subject.

The invention provides a probe set and a kit for detecting a pathogenic gene of an autoinflammatory disease. The probe set comprises probes capable of simultaneously specifically capturing pathogenicgenes affecting inflammasome defects, non-inflammasome defects and autoinflammatory diseases associated with defects in an interferon pathway. The probe set and the kit for detecting the pathogenic gene of the autoinflammatory disease are capable of simultaneously detecting the pathogenic genes of 50 types of known autoinflammatory diseases; based on the probe set which is high in targeted screening, stable and reliable in gene acquisition and used for detecting the pathogenic gene of the autoinflammatory disease, and combined with a high-throughput sequencing method, a diagnosis cycle of theautoinflammatory disease can be accelerated, the diagnostic efficiency can be improved, and several new diseases can be diagnosed, especially for children with the autoinflammatory diseases, so that the effects of no missed detection, no missed diagnosis, relatively small amount of data analysis, shortened inspection cycle are achieved.

The invention belongs to the field of biomedicine, and relates to a fusion protein for sub-cellular localization and an application thereof. A system can be used for reporting the activity of inflammasomes on the organelle level mainly based on secretion type luciferase. 7 kinds of plasmids included in the system are mainly obtained by sequentially cloning an organelle localization gene, an interleukin 1beta precursor coding gene (pro-IL-1beta) and secretion type luciferase (DN-Gluc) to a multiple cloning site zone of an expression vector pcDNA3.1. The plasmids included in the system are transfected to target cells respectively, and the activity of the inflammasomes can be quantitatively analyzed by detecting the activity of luciferase in extracellular supernate, so that the system has the advantages of high efficiency, fastness, simplicity, convenience and the like and can be applied to medicament screening, molecular mechanisms, live animal research and development of related products related to the inflammasomes.

Sickle cell patients atypically experience exaggerated inflammatory responses to pathogens that normally cause mild respiratory infections in non-sickle cell humans. There appears to be heightened inflammatory responses to pathogens in combination with hypoxia in sickle cell disease. The novelty of this invention provides a new paradigm to explain the exaggerated inflammatory response of sickle cell disease to pathogens especially when accompanied by hypoxic stress. In particular, sickle cell chest injury and other complications associated with ischemia-reperfusion injury caused by vaso-occlusion can involve co-stimulation of the NALP-3 inflammasome by pathogen associated molecular patterns (PAMPs) and hypoxic-induced danger associated molecular patterns (DAMPs), leading to exaggerated pro-inflammatory responses marked by increased IL-1β secretion and subsequent induction of neutrophilic inflammation. This invention thereby provides the immunologic, biologic and biochemical rationale for IL-1β targeted therapies in sickle cell disease to block the pathological effects of IL-1β that leads to exaggerated inflammatory expressions, including neutrophilic inflammation.

The invention relates to application of disulfiram in preparing drugs for preventing and treating diseases related to NLRP3 inflammasome. During research, phenomena are found that the disulfiram can effectively inhibit activation of the NLRP3 inflammasome and inhibit maturation and secretion of an inflammatory activation signal molecule Caspase-1P20 and an inflammatory cytokine IL-1[beta], accordingly has good prevention and treatment effects on the diseases related to the NLRP3 inflammasome, and especially has significant prevention and treatment effects on peritonitis and gouty arthritis.

The invention discloses application of berberine in preparation of medicines for enhancing inflammasome activation. The inventor discovers that berberine can achieve the effects of obviously promoting inflammasome activation induced by signals such as ATP and the like, improving activity of caspase-1 and secretion of mature IL-1beta, further promoting bacteria killing effects of macrophage and obviously increasing survival rate of mice in an intra-abdominal bacterial infection model, so that the berberine can enhance functions of innate immunocytes such as macrophage and the like and obviously improving resistance of the host to bacterial infection by promoting secretion of IL-1beta. Therefore, the berberine can be used for preparing inflammasome activation enhanced drugs. The drug can achieve the effects of enhancing functions of the innate immunocytes and treating systemic bacterial infection and other related diseases.

The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the severity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilitation efforts, and monitor response to treatment for a patient with a central nervous system injury are also described.

The invention discloses a sulfonamide compound with tetrahydroquinoline as a core and a preparation method and application of the sulfonamide compound. The sulfonamide compound with tetrahydroquinoline as the core is novel in structure and simple in preparation method, is capable of reducing mature secretion of interleukin IL-1beta by specifically inhibiting activation of NLRP3 inflammasome, thenalleviating inflammatory injury and improving inflammatory microenvironments, has remarkable anti-inflammation activity, and meanwhile has no conspicuous toxicity for THP-1 cells. The compound disclosed by the invention can be prepared as an anti-inflammation medicine for treating inflammation related diseases, including purpurin-related periodic syndromes, inflammatory intestine problems, chronicretardant lung diseases, diabetes, rheumatic arthritis, rheumatoid arthritis, gout, non-alcoholic fatty liver diseases, chronic kidney diseases, atherosclerosis, neurodegenerative diseases and the like.

The invention discloses application of echinatin serving as an inflammation inhibitor. The echinatin can serve as an inflammasome inhibitor, and can inhibit formation of apoptosis-associated speck-like protein (ASC) spots as well as subsequent activation of caspase-1 p20 and secretion of IL-1beta. The echinatin can serve as a potential drug for treating of diseases related to abnormal activation of inflammasomes.

The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I):wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

The present invention provides compositions and methods for reducing inflammation in the lungs of a mammal that is afflicted by a condition that leads to inflammation in the lungs. The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellularvesicle uptake inhibitor(s).

The invention discloses application of a hydrogen molecule solid carrier in preparation of medicine for preventing and treating obesity related metabolic inflammation. According to the hydrogen molecule solid carrier, molecular hydrogen achieves a physiological effect, the carrier does not achieve the physiological effect, the reducing effect of hydrogen can be fully achieved, and prevention and treatment of obesity related metabolic inflammation are achieved from multiple levels. The application includes the steps of inhibiting increase of serum inflammatory factors in the generating process of obesity related metabolic inflammation, inhibiting increase of adipose tissue inflammatory factors, relieving adipose tissue dyslipidemia, inhibiting generation of oxidative damage in adipose tissue and inhibiting activation of inflammasome in the adipose tissue. The result shows that the hydrogen molecule solid carrier is fairly effective medicine for preventing and treating obesity related metabolic inflammation.

The invention discloses an application of an exosome in preparation of drugs or cosmetics for repairing skin injury, belonging to the technical field of skin treatment. In order to solve the problem of skin injury, the exosome provided by the invention is obtained through the following steps: separating mesenchymal stem cells from primary cornu cervi pantotrichum tissues; and carrying out in-vitroamplification culture, collecting a cell culture solution, and carrying out separation and extraction so as to obtain an antler mesenchymal stem cell-derived exosome. The exosome provided by the invention is proved to be able to inhibit LPS induced inflammatory response of HaCat cells through an NLRP3 inflammasome signaling pathway, accelerate wound repair of a mouse model with skin injury and relieve inflammatory response. The exosome provided by the invention can be used for preparing the drugs or the cosmetics for treating skin injury repairing.

The invention relates to the technical field of new applications of drugs and especially relates to an application of panax notoginseng saponins in preparing NLRP3 inflammasome-restraining drugs or drugs for treating tristimania. A test result proves that panax notoginseng saponins is capable of obviously restraining activation of LPS-induced rat hippocampal microglia and release of NLRP3 inflammasome and IL-1 beta and IL-18 and can be used for treating tristimania induced by abnormal increasing of microglia NLRP3 inflammasome.

The invention discloses application of BRLF1 in the preparation of preparations to inhibit activity of Herpes virus-activated inflammasomes, and also discloses a BRLF1 functional small peptide which may act on inflammasome activity pathways and has a broad-spectrum inhibitory function for the activity of inflammasomes. After a small peptide is conjugated with and passed through a signal peptide, good penetrating property is provided; the functional small peptide can enter cells directly to better give rise to the effect of inhibiting the activity of inflammasomes.

The invention relates to a class of 1, 2, 3, 5, 6, 7 hexahydrosymmetric indacene compounds containing one or more substituents., pharmaceutically acceptable salts, esters or hydrates thereof, a preparation method thereof, a pharmaceutical composition containing the compounds, and an application of the compounds as a novel NLRP3 inflammasome inhibitor in preparation of drugs for preventing and / or treating diseases related to NLRP3 inflammasome.

The invention discloses application of a Compound C in preparation of a medicine used for treating a non-alcoholic fatty liver disease (NAFLD). Experimental results show that the Compound C is provedto be capable of effectively inhibiting NLRP3 inflammasome and inflammation reaction by virtue of experiments, so that formation of the NAFLD is obviously reduced. Therefore, a research foundation anda theoretical basis are provided for development of medicines used for treating the NAFLD.

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof:wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 or R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.

A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and / or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone or in combination with a statin and / or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and / or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and / or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.